Direct Healthcare Professional Communication (DHPC) on etoposide (not etoposide phosphate): hypersensitivity reactions with the use of inline filters
2023.12.14
Active substance: etoposide
The marketing authorization holders of medicinal products containing etoposide (not etoposide phosphate), in consultation with the Federal Institute for Drugs and Medical Devices (BfArM), inform that an increased risk of infusion-related hypersensitivity reactions has been observed with the use of inline filters during the administration of medicinal products containing etoposide. Inline filters should not be used when administering medicinal products containing etoposide. The recommendations apply only to etoposide and not to etoposide phosphate.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN